跳至主要内容
临床试验/NCT00240214
NCT00240214终止不适用

An Open Label Post Marketing Surveillance Assessment to Evaluate the Effectiveness and Safety of Rapamune in Patients After Kidney Transplantation Receiving a Rapamune Containing Regime

Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 500 人开始时间: 2001年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
终止
发起方
入组人数
500

研究概览

简要总结

The purpose of this study is to obtain data on the effectiveness and safety of Rapamune under everyday conditions

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients having received a renal allograft from a cadaveric or living donor with low or moderate risk of developing acute rejection episodes.

排除标准

  • Contraindications according to Summary of the Product Characteristics (SmPC).

研究组 & 干预措施

1

sirolimus

干预措施: sirolimus (Drug)

研究者

发起方
Wyeth is now a wholly owned subsidiary of Pfizer
申办方类型
Industry

相似试验

Study Evaluating Rapamune in Patients After Kidney... | 临床试验